Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Colin P. Dinney, Trinity J. Bivalacqua et al.|The Lancet Oncology|2020Cited by 459
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M. Narayan, Colin P. Dinney, Stephen A. Boorjian et al.|The Journal of Urology|2024Cited by 80
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P. Mitra, Colin P. Dinney, Vikram M. Narayan et al.|European Urology|2021Cited by 24